65 research outputs found
Effect of vitamin D and interferon Ξ±-2b on cytokine profile in pregnant women with vaginal infections
A study was conducted to evaluate effectiveness of vitamin D and interferon Ξ±-2b preparations on cytokine profile in pregnant women with vaginal infections. It was shown that pregnant women with vs. without bacterial vaginosis were featured with low vitamin D level in 53.8β60.5% cases. Administration of vitamin D and interferon Ξ±-2b preparations in combination with antibacterial therapy in pregnant women with bacterial vaginosis conferred anti-inflammatory effect resulting in normalized IL-8 level corresponding to that one in healthy subjects. Use of vitamin D altered interferon status and augmented antimicrobial activity in pregnant women confirmed by reduced rate of ARI episodes
Application of bacterial therapeutic vaccine Immunovac-VP4 in the treatment of pollinosis
In-depth study of the function and structure of the lymphoid tissue of the gastrointestinal tract and respiratory tract opens wide opportunities for the use of mucosal vaccines to improve immunity to various infectious agents. One such drug is The immunovac-VP4 vaccine containing pathogen-associated molecular structures (PAMSs) of microorganisms. They are the antigens of Klebsiella pneumoniae, Proteus vulgaris, Escherichia coli, Staphylococcus aureus. Discovered in many studies and experiments, the ability of the vaccine to induce innate immunity provides opportunities for prevention and treatment of both infections and allergic diseases, because it promotes the switching of Th2 immune response to Th1. The aim of the study was to study the effectiveness of the complex use of bacterial therapeutic vaccine Immunovac-VP4 and allergen-specific immune therapy (ASIT) in pollinosis in children and adults. Materials and methods. Bacterial therapeutic vaccine Immunovac-VP4 was used annually, nasal and oral administration in patients before the course of ASIT standardized aqueous-salt solutions of allergens. Results. The therapeutic application of bacterial vaccines, Immunoac-ΠΠ4 before the course ASIT has helped to reduce the frequency of acute respiratory infections in 8,5 times in comparison with the control group. Clinical efficacy of complex treatment according to the results of the survey of patients in 7 years after the start of therapy was 90%. There was a significant decrease In IgG4 to causally significant allergens, General immnunoglobulin E (IgE) and a tendency to decrease IgE. Conclusion. The use of bacterial therapeutic vaccine Immunovac-VP4, which is a natural ligand of toll-like receptors in combination with ASIT, seems to be an effective and promising direction in the treatment of allergic diseases
Comparative effect of immunomodulators on the contents of hydrolase inhibitors and lactoferrin in community-acquired pneumonia in adults
TheΒ purposeΒ of ourΒ studyΒ was toΒ examine theΒ effectΒ of immunomodulators (broncho-vaxom, immunovac-VP4 vaccineΒ and polyoxidonium) uponΒ the kineticsΒ of serum hydrolase inhibitors and lactoferrin in the treatment of community-acquired pneumonia (CAP). TheΒ study included 71 CAPΒ patients at the age of 18 to 70 years. TheΒ patients were dividedΒ intoΒ 4 groups:Β Group I (15 people)Β was a control groupΒ treated with basic antibacterial andΒ symptomatic therapy, according to the standard treatment regimen, without use of immunomodulators; theΒ patients fromΒ groupΒ IIΒ (19Β patients) wereΒ additionally administered bronchovaxom (theΒ drug was prescribed uponΒ admission: 1 courseΒ over 30 days, thenΒ 2 roundsΒ for 10 days each,Β with an intervalΒ in 20 days); group IIIΒ (20 cases) contained the patients who additionally receivedΒ polyoxidonium (the drug was prescribed from the 1st day of hospitalization, 6 mg daily i/mΒ for 3 days, thenΒ 10 injections over 10 days); group IV (17 cases): Immunovac-VP4 vaccineΒ was administered orally 4 ml and intranasally 2 drops on days 1, 4, 7, 10, 13, 19, 25, 31, alongΒ with antibacterial andΒ symptomatic therapy. ThisΒ vaccineΒ consists ofΒ antigensΒ Β fromΒ opportunistic microorganisms (aΒ multicomponentΒ mixture ofΒ water-soluble antigensΒ Β of S. aureus, K. pneumoniae, P. vulgaris, E. coli). SerumΒ concentrations of Ξ±2-macroglobulin and Ξ±1-antitrypsin hydrolase inhibitors were determined by the method of quantitative immunoelectrophoresis using the research test systems; lactoferrin (LF)Β levels were evaluated by enzyme-linked immunosorbent assay using commercial test systems. TheseΒ indicators were studiedΒ in blood serumΒ before treatment, on the 2nd, 13th, and 60thΒ Β days of observation. It was shown that administration of immune modulators combined with antibiotic therapyΒ in patients with CAP can affect the kinetics of acute phase inflammatory proteins. The effect of broncho-vaxom corresponds to the classical pathway of the response to inflammatory process, i.e., activation of complex of positive acute phase reactants (Ξ±1-antitrypsin andΒ lactoferrin) andΒ inhibition (blocking) of negativeΒ acuteΒ phaseΒ reactants (Ξ±2macroglobulin). Polyoxidonium has a noticeable effect only upon neutrophils secreting lactoferrin. ImmunovacVP4 promotes only short-term secretion of this protein. One may assume that activation of hydrolase inhibitors and lactoferrin after use of immunotropic drugs enhances clinical effect of therapy, with decreased severity and duration of symptoms, as well as lower exacerbation risk of chronic diseases and lesser volumeΒ of drug intake. Antibacterial therapyΒ does not significantlyΒ affect the kinetics of acute phase inflammation reactants in patients with CAP.Β Administration of immunomodulators in combination with standard basic therapyΒ may affects the inflammatory process to differentΒ degree,Β thus, in turn,Β leading to improved prognosisΒ in this disease
ROLE OF ANGIOGENIC FACTORS FOR TRANSPLACENTAL TRANSFER OF THE MEASLES ANTIBODIES
Angiogenesis factors (VEGF, Ang-1, TGF-Ξ²) influence production, development and functioning of vascular endothelium that are part of the placental barrier structure and are involved into transplacental transfer of different substances. The aim of this study was to study the relationship between VEGF, Ang-1, and TGF-Ξ² concentrations, and the levels of transplacental IgG-antibodies to the measles virus in cord blood of children born to mothers with placental insufficiency. Patients and methods: venous blood was taken from 32 women with uncomplicated pregnancies, and 34 samples from pregnant women with placental insufficiency, as well as umbilical blood of their newborns, the level of IgG-antibodies to measles and the concentration of some angiogenic factors (VEGF, Ang-1, TGF-Ξ²) examined by ELISA techniques. The following results were obtained: in a cord blood of infants seronegative for the measles virus, born to women with placental insufficiency, showed uniformly low VEGF levels, decreased Ang-1 concentration (1.6) and increased TGF-Ξ² concentration (2.7) as compared to seropositive newborns. In a similar group of children from mothers with physiological pregnancy, the level of these factors did not differ from those in newborns with protective antibodies to measles. Conclusion: in physiological pregnancy, transplacental transmission of IgG-antibodies to the measles virus is directly dependent on the presence of specific antibodies in a woman; in case of placental insufficiency, an imbalance in the system of angiogenic factors may promote disturbances of transmission mechanisms for IgG measles-specific antibodies from mother to the fetus
ΠΠ΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΊΠΎΠΊΠ»ΡΡΠ½ΡΡ Π²Π°ΠΊΡΠΈΠ½ Ρ ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠΎΠ²
Aim: to investigate the safety of acellular pertussis vaccines for adolescents.Materials and methods. The clinical tolerability of revaccination against pertussis (cell-free component), diphtheria and tetanus was analyzed in 107 children aged 13,5β14 years. Group 1 consisted of children revaccinated with DTacP-IPV combined vaccine (Tetraxim), group 2 β vaccinated with Td and group 3 β children who received Tdap vaccine (Adacel).Results. Statistically significant differences in the frequency of local reactions between the group that received Tdap and the other two (DTacP-IPV and Td) were detected (p = 0.001and p = 0.04, respectively). Analysis of the structure of local reactions revealed a difference only in the occurrence of the hyperemia at the site of injection, with the most frequent registration in the groups of children vaccinated with DTacPIPV (29,4%) and Td (14,7%), whereas in patients vaccinated with Tdap β only in 5,9% (Ο2 = 6,8 p = 0,03). Systemic reactions occurred with the same frequency in all studied groups and did not require medical correction, as well as local reactions. Thus, revaccination against pertussis, diphtheria and tetanus of adolescents using Tdap, containing the acellular pertussis component, does not exceed the frequency of systemic reactions and the number of local reactions is significantly lower in comparison with the vaccine with a reduced content of diphtheria and tetanus toxoids (Td) that is used in practice for a long time.Π¦Π΅Π»Ρ: ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π°ΡΠ΅Π»Π»ΡΠ»ΡΡΠ½ΡΡ
ΠΊΠΎΠΊΠ»ΡΡΠ½ΡΡ
Π²Π°ΠΊΡΠΈΠ½ Ρ ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠΎΠ².ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠΌΠΎΡΡΠΈ ΡΠ΅Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² ΠΊΠΎΠΊΠ»ΡΡΠ° (Π±Π΅ΡΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΉ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ), Π΄ΠΈΡΡΠ΅ΡΠΈΠΈ ΠΈ ΡΡΠΎΠ»Π±Π½ΡΠΊΠ° Ρ 107 Π΄Π΅ΡΠ΅ΠΉ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ 13,5β14 Π»Π΅Ρ. 1 Π³ΡΡΠΏΠΏΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ Π΄Π΅ΡΠΈ, ΡΠ΅Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ ΠΠ±ΠΠΠ‘-ΠΠΠ (Π’Π΅ΡΡΠ°ΠΊΡΠΈΠΌ), 2 Π³ΡΡΠΏΠΏΡ β ΠΏΡΠΈΠ²ΠΈΡΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ ΠΠΠ‘-Π ΠΈ 3 Π³ΡΡΠΏΠΏΡ β Π΄Π΅ΡΠΈ, ΠΏΠΎΠ»ΡΡΠΈΠ²ΡΠΈΠ΅ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΠ±ΠΠΠ‘-Π (ΠΠ΄Π°ΡΠ΅Π»Ρ).Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΡΠ²Π»Π΅Π½Ρ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΠ΅ ΡΠ°Π·Π»ΠΈΡΠΈΡ ΠΏΠΎ ΡΠ°ΡΡΠΎΡΠ΅ Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΠΈ ΠΌΠ΅ΡΡΠ½ΡΡ
ΡΠ΅Π°ΠΊΡΠΈΠΉ ΠΌΠ΅ΠΆΠ΄Ρ Π³ΡΡΠΏΠΏΠΎΠΉ, ΠΏΠΎΠ»ΡΡΠΈΠ²ΡΠ΅ΠΉ ΠΠ±ΠΠΠ‘-Π, ΠΈ Π΄Π²ΡΠΌΡ Π΄ΡΡΠ³ΠΈΠΌΠΈ (ΠΠ±ΠΠΠ‘-ΠΠΠ ΠΈ ΠΠΠ‘-Π) (p=0,001 ΠΈ p=0,04 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). ΠΠ½Π°Π»ΠΈΠ· ΡΡΡΡΠΊΡΡΡΡ ΠΌΠ΅ΡΡΠ½ΡΡ
ΡΠ΅Π°ΠΊΡΠΈΠΉ Π²ΡΡΠ²ΠΈΠ» ΡΠ°Π·Π»ΠΈΡΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΡΠΎΠ»ΡΠΊΠΎ ΠΏΠΎ ΡΠ°ΡΡΠΎΡΠ΅ Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΡ Π³ΠΈΠΏΠ΅ΡΠ΅ΠΌΠΈΠΈ Π½Π° ΠΌΠ΅ΡΡΠ΅ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ, ΠΊΠΎΡΠΎΡΠ°Ρ Π±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΠΎ ΠΎΡΠΌΠ΅ΡΠ°Π»Π°ΡΡ Π² Π³ΡΡΠΏΠΏΠ°Ρ
Π΄Π΅ΡΠ΅ΠΉ, ΠΏΡΠΈΠ²ΠΈΡΡΡ
ΠΠ±ΠΠΠ‘-ΠΠΠ (29,4%) ΠΈ ΠΠΠ‘-Π (14,7%), ΡΠΎΠ³Π΄Π° ΠΊΠ°ΠΊ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΡΠ΅Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΠ±ΠΠΠ‘-Π, ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π»Π°ΡΡ ΡΠΎΠ»ΡΠΊΠΎ Π² 5,9% (Ο2 =6,8 p=0,03). Π‘ΠΈΡΡΠ΅ΠΌΠ½ΡΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π²ΡΡΡΠ΅ΡΠ°Π»ΠΈΡΡ Ρ ΠΎΠ΄ΠΈΠ½Π°ΠΊΠΎΠ²ΠΎΠΉ ΡΠ°ΡΡΠΎΡΠΎΠΉ Π²ΠΎ Π²ΡΠ΅Ρ
ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΡ
Π³ΡΡΠΏΠΏΠ°Ρ
ΠΈ Π½Π΅ ΡΡΠ΅Π±ΠΎΠ²Π°Π»ΠΈ ΠΌΠ΅Π΄ΠΈΠΊΠ°ΠΌΠ΅Π½ΡΠΎΠ·Π½ΠΎΠΉ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΠΈ, ΡΠ°ΠΊ ΠΆΠ΅, ΠΊΠ°ΠΊ ΠΈ ΠΌΠ΅ΡΡΠ½ΡΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, ΡΠ΅Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΡ ΠΏΡΠΎΡΠΈΠ² ΠΊΠΎΠΊΠ»ΡΡΠ°, Π΄ΠΈΡΡΠ΅ΡΠΈΠΈ ΠΈ ΡΡΠΎΠ»Π±Π½ΡΠΊΠ° ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠΎΠ² Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΠ±ΠΠΠ‘-Π, ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠ΅Π³ΠΎ Π±Π΅ΡΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΉ ΠΊΠΎΠΊΠ»ΡΡΠ½ΡΠΉ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ, Π½Π΅ Π²ΡΠ·ΡΠ²Π°Π΅Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ ΡΠ°ΡΡΠΎΡΡ ΡΠΈΡΡΠ΅ΠΌΠ½ΡΡ
ΡΠ΅Π°ΠΊΡΠΈΠΉ, Π° ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΌΠ΅ΡΡΠ½ΡΡ
ΡΠ΅Π°ΠΊΡΠΈΠΉ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π½ΠΈΠΆΠ΅ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΈΡ
Β Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΡΡ ΠΏΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ Π΄Π°Π²Π½ΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΠΎΠΉ Π½Π° ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅ Π²Π°ΠΊΡΠΈΠ½Ρ Ρ ΡΠΌΠ΅Π½ΡΡΠ΅Π½Π½ΡΠΌ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ΠΌ Π΄ΠΈΡΡΠ΅ΡΠΈΠΉΠ½ΠΎΠ³ΠΎ ΠΈ ΡΡΠΎΠ»Π±Π½ΡΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°ΡΠΎΠΊΡΠΈΠ½ΠΎΠ² ΠΠΠ‘-Π.
ΠΠΎΠ²ΡΠ΅ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ Π²Π°ΠΊΡΠΈΠ½ΠΎΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΊΠΎΠΊΠ»ΡΡΠ°
The review provides information about the current features of the spread of whooping cough among children and adolescents. It is shown that there is a shift in morbidity to an older age group of the population, which is facilitated by changes in the properties of the pathogen and the widespread use of drugs based on cell-free technology as primary vaccination. Information is given about the possibility of preventing morbidity among schoolchildren and adults by introducing additional revaccinating doses against whooping cough with special drugs in the vaccination calendars. Information is given on effective protection of newborns against this infection by immunization of pregnant women. In our country, there is an opportunity to expand pertussis immunoprophylaxis among children of preschool-school age and adults within regional programs and individual vaccination with acellular pertussis-diphtheria-tetanus vaccines, which has a high profile of safety and immunological effectiveness.Π ΠΎΠ±Π·ΠΎΡΠ΅ ΠΎΠ±ΠΎΠ±ΡΠ΅Π½Ρ Π΄Π°Π½Π½ΡΠ΅ ΠΎ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΡ
ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ ΠΊΠΎΠΊΠ»ΡΡΠ° ΡΡΠ΅Π΄ΠΈ Π΄Π΅ΡΠ΅ΠΉ ΠΈ ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠΎΠ². ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΠΏΡΠΎΠΈΡΡ
ΠΎΠ΄ΠΈΡ ΡΠΌΠ΅ΡΠ΅Π½ΠΈΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ Π² Π±ΠΎΠ»Π΅Π΅ ΡΡΠ°ΡΡΡΡ Π²ΠΎΠ·ΡΠ°ΡΡΠ½ΡΡ Π³ΡΡΠΏΠΏΡ, ΡΠ΅ΠΌΡ ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΡΡΡ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΠ²ΠΎΠΉΡΡΠ² Π²ΠΎΠ·Π±ΡΠ΄ΠΈΡΠ΅Π»Ρ ΠΈ ΠΏΠΎΠ²ΡΠ΅ΠΌΠ΅ΡΡΠ½ΠΎΠ΅ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ Π±Π΅ΡΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ. ΠΡΠΈΠ²Π΅Π΄Π΅Π½Ρ ΡΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΎ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΏΡΠ΅Π΄ΠΎΡΠ²ΡΠ°ΡΠ΅Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ ΡΡΠ΅Π΄ΠΈ ΡΠΊΠΎΠ»ΡΠ½ΠΈΠΊΠΎΠ² ΠΈ Π²Π·ΡΠΎΡΠ»ΡΡ
ΠΏΡΡΡΠΌ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ Π² ΠΊΠ°Π»Π΅Π½Π΄Π°ΡΠΈ ΠΏΡΠΈΠ²ΠΈΠ²ΠΎΠΊ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΡΠ΅Π²Π°ΠΊΡΠΈΠ½ΠΈΡΡΡΡΠΈΡ
Π΄ΠΎΠ· ΠΏΡΠΎΡΠΈΠ² ΠΊΠΎΠΊΠ»ΡΡΠ° Π±Π΅ΡΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌΠΈ Π²Π°ΠΊΡΠΈΠ½Π°ΠΌΠΈ. ΠΠ°ΡΡΡΡ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΏΠΎ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ Π·Π°ΡΠΈΡΠ΅ Π½ΠΎΠ²ΠΎΡΠΎΠΆΠ΄ΡΠ½Π½ΡΡ
ΠΏΡΠΎΡΠΈΠ² Π΄Π°Π½Π½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΏΡΡΡΠΌ ΠΈΠΌΠΌΡΠ½ΠΈΠ·Π°ΡΠΈΠΈ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
. Π ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΡΠ΅Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² ΠΊΠΎΠΊΠ»ΡΡΠ° ΡΡΠ΅Π΄ΠΈ Π΄Π΅ΡΠ΅ΠΉ Π΄ΠΎΡΠΊΠΎΠ»ΡΠ½ΠΎ-ΡΠΊΠΎΠ»ΡΠ½ΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° ΠΈ Π²Π·ΡΠΎΡΠ»ΡΡ
Π² ΡΠ°ΠΌΠΊΠ°Ρ
ΡΠ΅Π³ΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌ ΠΈ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½ΠΎΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡ Π±Π΅ΡΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠ΅ ΠΠ±ΠΠΠ‘-Π Π²Π°ΠΊΡΠΈΠ½Ρ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΈΠΌΠ΅ΡΡ Π²ΡΡΠΎΠΊΠΈΠΉ ΠΏΡΠΎΡΠΈΠ»Ρ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ
ΠΠ°ΠΊΡΠΈΠ½Π°ΡΠΈΡ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ ΠΏΡΠΎΡΠΈΠ² ΡΠΏΡΠ°Π²Π»ΡΠ΅ΠΌΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΠΊΡΠ°
The review provides information on the importance of immunoprophylaxis of epidemic controlled infections in pregnant women. It is shown that the most severe complicationsΒ of pregnancy occur when women are infected with respiratory pathogens, especially influenza virus in the late stagesΒ of gestation. Newborns also have a high risk of fatal disorders and an infant mortality rate in cases of maternal influenza. Modern inactivated vaccines used in pregnant womenΒ in many countries since the second period of gestation haveΒ high safety and immunological efficacy for both women andΒ the fetus. The issues of expediency, safety and effectivenessΒ of vaccination of pregnant women against pneumococcus,Β Hemophilus type-b and pertussis infection are actively discussed, which reflects the evolution of understanding of theΒ importance of this area of preventive medicine in obstetricpractice.Π ΠΎΠ±Π·ΠΎΡΠ΅ ΠΏΡΠΈΠ²ΠΎΠ΄ΡΡΡΡ ΡΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΎ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΠΈ Ρ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
ΠΈΠΌΠΌΡΠ½ΠΎΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΡΠΏΠΈΠ΄Π΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΏΡΠ°Π²Π»ΡΠ΅ΠΌΡΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΡΠΆΡΠ»ΡΠ΅Β ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ ΡΠ»ΡΡΠ°ΡΡΡΡ ΠΏΡΠΈ ΠΈΠ½ΡΠΈΡΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ ΠΆΠ΅Π½ΡΠΈΠ½ ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΡΠΌΠΈ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π°ΠΌΠΈ, ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΒ Π²ΠΈΡΡΡΠΎΠΌ Π³ΡΠΈΠΏΠΏΠ° Π½Π° ΠΏΠΎΠ·Π΄Π½ΠΈΡ
ΡΡΠΎΠΊΠ°Ρ
Π³Π΅ΡΡΠ°ΡΠΈΠΈ. ΠΠΎΠ²ΠΎΡΠΎΠΆΠ΄ΡΠ½Π½ΡΠ΅ Π΄Π΅ΡΠΈ ΡΠ°ΠΊΠΆΠ΅ ΠΈΠΌΠ΅ΡΡ Π²ΡΡΠΎΠΊΠΈΠΉ ΡΠΈΡΠΊ ΡΠ΅ΡΠ°Π»ΡΠ½ΡΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ ΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ ΠΌΠ»Π°Π΄Π΅Π½ΡΠ΅ΡΠΊΠΎΠΉ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΠΈ Π² ΡΠ»ΡΡΠ°ΡΡ
ΠΏΠ΅ΡΠ΅Π½Π΅ΡΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ Π³ΡΠΈΠΏΠΏΠ°. ΠΡΡΠΎΠΊΠΎΠΉ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡΡ ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ ΠΊΠ°ΠΊΒ Π΄Π»Ρ ΠΆΠ΅Π½ΡΠΈΠ½Ρ, ΡΠ°ΠΊ ΠΈ Π΄Π»Ρ ΠΏΠ»ΠΎΠ΄Π° ΠΎΠ±Π»Π°Π΄Π°ΡΡ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅Β ΠΈΠ½Π°ΠΊΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π²Π°ΠΊΡΠΈΠ½Ρ, ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΠΌΡΠ΅ Ρ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
Π²ΠΎ ΠΌΠ½ΠΎΠ³ΠΈΡ
ΡΡΡΠ°Π½Π°Ρ
ΠΌΠΈΡΠ°, Π½Π°ΡΠΈΠ½Π°Ρ Ρ Π²ΡΠΎΡΠΎΠ³ΠΎ ΠΏΠ΅ΡΠΈΠΎΠ΄Π°Β Π³Π΅ΡΡΠ°ΡΠΈΠΈ. ΠΠΊΡΠΈΠ²Π½ΠΎ ΠΎΠ±ΡΡΠΆΠ΄Π°ΡΡΡΡ Π²ΠΎΠΏΡΠΎΡΡ ΡΠ΅Π»Π΅ΡΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎΡΡΠΈ, Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈΒ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
ΠΏΡΠΎΡΠΈΠ² ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠ°, Π³Π΅ΠΌΠΎΡΠΈΠ»ΡΠ½ΠΎΠΉ ΡΠΈΠΏΠ° bΒ ΠΈ ΠΊΠΎΠΊΠ»ΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ, ΡΡΠΎ ΠΎΡΡΠ°ΠΆΠ°Π΅Ρ ΡΠ²ΠΎΠ»ΡΡΠΈΡ ΠΏΠΎΠ½ΠΈΠΌΠ°Π½ΠΈΡ Π²Π°ΠΆΠ½ΠΎΡΡΠΈ ΡΡΠΎΠ³ΠΎ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠΉΒ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Ρ Π² Π°ΠΊΡΡΠ΅ΡΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅
ΠΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΌΠΈΠΊΡΠΎΠ±Π½ΠΎΠ³ΠΎ ΠΏΠ΅ΠΉΠ·Π°ΠΆΠ° ΠΌΠΎΠΊΡΠΎΡΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ Π½Π° ΡΠΎΠ½Π΅ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠ°, Π³Π΅ΠΌΠΎΡΠΈΠ»ΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΡΠΈΠΏΠ° b ΠΈ Π³ΡΠΈΠΏΠΏΠ°
Summary. The influence of combined vaccination against Streptococcus pneumoniae, Haemophilus influenzae type b and influenza on sputum bacterial land scape in patients with chronic obstructive pulmonary disease (COPD) has been analyzed in this article. The 1st group of 31 COPD patients (mean age, 59.25 Β± 1.12 years) were vaccinated simultaneously with "Pneumo23", "Hiberix", "Grippol plus". The 2nd group consisted of 49 unvaccinated COPD patients (mean age, 57.16 Β± 0.98 years). We used a classical microbiological method. Three months after the complete vaccination, there was a significant decrease in number of patients with S. pneumoniae yielded in sputum in comparison with unvaccinated COPD patients.Π Π΅Π·ΡΠΌΠ΅. Π¦Π΅Π»ΡΡ ΡΠ°Π±ΠΎΡΡ Π±ΡΠ»ΠΎ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ Π²Π»ΠΈΡΠ½ΠΈΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠ°, Π³Π΅ΠΌΠΎΡΠΈΠ»ΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΡΠΈΠΏΠ° b ΠΈ Π³ΡΠΈΠΏΠΏΠ° Π½Π° ΠΌΠΈΠΊΡΠΎΠ±Π½ΡΠΉ ΠΏΠ΅ΠΉΠ·Π°ΠΆ ΠΌΠΎΠΊΡΠΎΡΡ ΡΠ΅ΡΠ΅Π· 3 ΠΌΠ΅Ρ. ΠΏΠΎΡΠ»Π΅ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ
(Π₯ΠΠΠ) ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π½Π΅Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ. ΠΠ΅ΡΠ²ΡΡ Π³ΡΡΠΏΠΏΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Π₯ΠΠΠ (n = 31), ΠΎΠ΄Π½ΠΎΠΌΠΎΠΌΠ΅Π½ΡΠ½ΠΎ Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ "ΠΠ½Π΅Π²ΠΌΠΎ23", "Π₯ΠΈΠ±Π΅ΡΠΈΠΊΡ", "ΠΡΠΈΠΏΠΏΠΎΠ» ΠΏΠ»ΡΡ" (ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ β 59,25 Β± 1,12 Π³ΠΎΠ΄Π°), Π²ΡΠΎΡΡΡ Π³ΡΡΠΏΠΏΡ β Π½Π΅Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Π₯ΠΠΠ (n = 49) (ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ β 57,16 Β± 0,98 Π³ΠΎΠ΄Π°). ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΡΡ ΠΊΠ»Π°ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΌΠΈΠΊΡΠΎΠ±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΌΠ΅ΡΠΎΠ΄. Π§Π΅ΡΠ΅Π· 3 ΠΌΠ΅Ρ. ΠΠΎΡΠ»Π΅ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΡΠΈΡΠ»Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π²ΡΠ΄Π΅Π»ΡΡΡΠΈΡ
Ρ ΠΌΠΎΠΊΡΠΎΡΠΎΠΉ Streptococcus pneumoniae, ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π½Π΅Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌΠΈ Π±ΠΎΠ»ΡΠ½ΡΠΌΠΈ Π₯ΠΠΠ
- β¦